Study S001849

Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04174755
Acronym: SWIFT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: RECRUITING
Enrollment: 80
Start: 2022-06-22
Primary completion: 2027-01
Lead sponsor: University College Dublin
Conditions: Obesity; HIV-1-infection
Interventions: DRUG:Semaglutide Injectable Product; BEHAVIORAL:Standard of care
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Changes in total body weight (in Kg) [28 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004841	Are glucagon-like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV? Bottanelli M, HIV medicine	2024	Nonrandomized study	PMID 37990373 DOI	cites ClinicalTrials.gov:NCT04174755
R0027399	An enhanced participant information leaflet and multimedia intervention to improve the quality of informed consent to a randomised clinical trial enrolling people living with HIV and obesity: a protocol for a Study Within A Trial (SWAT). O'Sullivan L, Trials	2022	Protocol	PMID 35039057 DOI	cites ClinicalTrials.gov:NCT04174755; registry reference DERIVED:35039057